Media coverage about T2 Biosystems (NASDAQ:TTOO) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. T2 Biosystems earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news stories about the medical equipment provider an impact score of 46.2329925330536 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
NASDAQ:TTOO traded down $0.06 during midday trading on Wednesday, reaching $6.57. The company had a trading volume of 256,263 shares, compared to its average volume of 556,047. T2 Biosystems has a 12-month low of $3.60 and a 12-month high of $9.98. The company has a current ratio of 7.31, a quick ratio of 7.10 and a debt-to-equity ratio of 1.22.
T2 Biosystems (NASDAQ:TTOO) last announced its quarterly earnings results on Thursday, August 2nd. The medical equipment provider reported ($0.32) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.32). The company had revenue of $3.90 million during the quarter, compared to the consensus estimate of $2.97 million. T2 Biosystems had a negative return on equity of 556.22% and a negative net margin of 637.62%. T2 Biosystems’s revenue for the quarter was up 307.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.50) EPS. sell-side analysts forecast that T2 Biosystems will post -1.32 earnings per share for the current year.
A number of research analysts recently issued reports on TTOO shares. Janney Montgomery Scott upgraded T2 Biosystems from a “neutral” rating to a “buy” rating in a report on Wednesday, May 9th. HC Wainwright set a $9.00 target price on T2 Biosystems and gave the company a “buy” rating in a report on Wednesday, May 9th. Zacks Investment Research lowered T2 Biosystems from a “hold” rating to a “sell” rating in a report on Wednesday, May 9th. ValuEngine upgraded T2 Biosystems from a “hold” rating to a “buy” rating in a report on Friday, May 18th. Finally, BidaskClub upgraded T2 Biosystems from a “hold” rating to a “buy” rating in a report on Thursday, May 24th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $8.05.
About T2 Biosystems
T2 Biosystems, Inc, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine.
Read More: Hedge Funds – How They Work For Investors
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.